Strong Growth Ahead: Diabetic Macular Edema (DME) Market Size To Grow At Arecord 4.4% Cagr By 2029

We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

How Big Is the Diabetic Macular Edema (DME) Market Size Expected to Be by 2034?
There has been a consistent increase in the market size for Diabetic Macular Edema (DME) recently. Projected growth forecasts show a rise from $4.67 billion in 2024 to $4.89 billion in 2025, with a compound annual growth rate (CAGR) of 4.7%. The notable expansion during the historical period is linked to factors such as the increasing occurrence of diabetes, the growth in disorders related to edema, a surge in cases of diabetic eye diseases, a rise in the elderly population, and an increase in instances of blindness.

The market for diabetic macular edema (DME) is predicted to experience consistent expansion in the coming years, reaching a value of $5.82 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. Factors contributing to this growth during the forecast period could include improved access to healthcare, increased government funding for healthcare, heightened public awareness of diabetes-related complications, wider use of telemedicine for eye care, and the proliferation of specialized centers for diabetes-related eye care. Notable trends projected for this period include the development of anti-VEGF therapies, the increasing use of corticosteroid implants, enhancements in drug delivery systems, advances in retinal laser treatments, the rise of AI-powered diagnostic tools, and the trend towards minimally invasive surgical methods.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21169

What Are the Emerging Segments Within the Diabetic Macular Edema (DME) Market?
The diabetic macular edema (DME) market covered in this report is segmented -

1) By Treatment: Anti-VEGF Therapy, Corticosteroids, Laser Therapy, Surgical Intervention
2) By Disease Stage: Early Stage, Moderate Stage, Advanced Stage
3) By Patient Demographics: Adults, Elderly, Children
4) By Route Of Administration: Intravitreal Injection, Topical, Systemic
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Anti-VEGF Therapy: Monoclonal Antibodies, Recombinant Protein-Based Therapies
2) By Corticosteroids: Intravitreal Steroid Injections, Injectable Sustained-Release Corticosteroids
3) By Laser Therapy: Focal Laser Photocoagulation, Panretinal Photocoagulation
4) By Surgical Intervention: Vitrectomy, Membrane Peeling

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21169&type=smp

What Long-Term Drivers Are Shaping Diabetic Macular Edema (DME) Market Trends?
The growth of the diabetic macular edema (DME) market is likely to be propelled by the rising incidence of diabetes. Various factors such as an inactive lifestyle, poor eating habits, escalating obesity levels, aging societies and genetic susceptibility contribute to the growing prevalence of diabetes. Diabetic macular edema is caused by diabetes due to the damage it inflicts on the retinal blood vessels, causing fluid leak into the macula leading to swelling. For instance, the US-based public health research institute, the Institute for Health Metrics and Evaluation, reported in June 2023 that over half a billion people worldwide have diabetes. This number is set to more than double by 2050, increasing to 1.3 billion individuals. Consequently, the surging occurrence of diabetes is fueling the expansion of the diabetic macular edema (DME) market.

Who Are the Top Competitors in Key Diabetic Macular Edema (DME) Market Segments?
Major companies operating in the diabetic macular edema (DME) market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Novartis AG, Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals, Carl Zeiss Meditec AG, Bausch & Lomb, Santen Pharmaceutical Co. Ltd., Carl Zeiss AG, Topcon Corporation, Ypsomed AG, ARKRAY Inc, Hugel Inc., Optos plc, Noven Pharmaceuticals Inc., Alimera Sciences Inc., Allergan plc.

What Trends Are Driving Growth in The Diabetic Macular Edema (DME) Market?
Leading businesses in the diabetic macular edema (DME) treatment sector are concentrating their efforts on hi-tech developments, including cutting-edge drug therapies, in their aim to enhance patient treatment and management. The use of innovative treatment options rooted in new technology and research, these advanced drug therapies aim to increase efficacy, lessen side effects, and provide superior results for those under their care. For example, in March 2022, Beovu received approval from the European Commission for the treatment of visual impairment due to diabetic macular edema (DME), announced by Novartis AG, a pharmaceutical corporation based in Switzerland. The endorsement hinged on the outcomes of Phase III KESTREL and KITE studies, which posited Beovu's effectiveness as similar to aflibercept in terms of visual improvement after a year. Impressively, more than half of the patients treated with Beovu adhered to a 12-week treatment schedule, experiencing less retinal fluid than those treated with aflibercept.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/diabetic-macular-edema-dme-global-market-report

Which Regions Are Becoming Hubs for Diabetic Macular Edema (DME) Market Innovation?
North America was the largest region in the diabetic macular edema (DME) market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic macular edema (DME) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Diabetic Macular Edema (DME) Market?
2. What is the CAGR expected in the Diabetic Macular Edema (DME) Market?
3. What Are the Key Innovations Transforming the Diabetic Macular Edema (DME) Industry?
4. Which Region Is Leading the Diabetic Macular Edema (DME) Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.